Stevanato Group and Gerresheimer AG Announce Collaboration on the Development of an Innovative Ready-To-Use Vial Platform for the Pharmaceutical Industry
September 07 2022 - 6:00AM
Business Wire
The two leading companies joined forces to develop a new
Ready-To-Use vial solution, based on EZ-fill® pre-sterilized
platform, allowing seamless integration into standard fill &
finish lines, helping customers gaining significant increase in
quality and efficiency
Stevanato Group S.p.A. (NYSE: STVN), a global provider of drug
containment, drug delivery and diagnostic solutions to the
pharmaceutical, biotechnology and life sciences industries, and
Gerresheimer AG, a leading global provider of healthcare &
beauty and drug delivery systems for pharma, biotech and cosmetics,
announce that they have jointly developed a high-end Ready-To-Use
(RTU) solution platform with an initial focus on vials, based on
Stevanato Group’s market-leading EZ-fill® technology. This
collaboration is projected to help customers gain efficiencies,
improve the quality standard, increase speed to market, reduce
total cost of ownership (TCO) and help mitigate supply chain
risk.
Stevanato Group and Gerresheimer AG are addressing rising demand
for RTU vials in the market and the partnership serves as a market
enabler to fully support customers’ evolving needs and establish a
gold standard in the industrial filling process. The collaboration
aims to make RTU vials a standard, available to a wide number of
pharma companies globally – offering premium quality solutions to
patients and reducing complexity for pharma operations. The new
solution will be available to other players in the market to
standardize fill-finish operations from early phase drug
development to commercialization. The new RTU solution platform
from Stevanato Group and Gerresheimer AG will share the same
secondary packaging, production process and sterilization method,
ensuring consistent available capacity and a reliable double
sourcing to the pharmaceutical industry. A hallmark of the new RTU
platform is a significant reduction in particles, improving the
overall quality and performance of the RTU solutions. In addition,
customers can count on a high-end solution made by two major
players in the drug containment industry with a long history of
innovation. The new jointly developed vial platform and trademark
will be presented in detail to the market at the CPhI Worldwide in
Frankfurt in November 2022.
“Our EZ-fill® vial platform is the market’s
most established choice for pre-sterilized containers, and this
enhanced version for RTU vials will bring to the market its full
potential in terms of quality, flexibility and value for
Pharmaceutical Companies and CMOs,” said Mauro Stocchi, Chief
Business Officer at Stevanato Group. “Through our collaboration
with Gerresheimer AG we are responding to market demand, and we
expect to achieve another important milestone in creating a
reliable ecosystem to support, accelerate and de-risk the
conversion from bulk to EZ-fill® vials already underway in the
market.”
“The new developed RTU vial platform stands
out in terms of quality, TCO and sustainability and takes the use
of RTU solutions like vials and, in the future, cartridges to a new
level,” said Dr. Lukas Burkhardt, Member of the Management Board of
Gerresheimer AG. "Due to the strong reduction of the particle load,
the quality is significantly increased. Our new innovative solution
will convince the market to significantly accelerate the conversion
from bulk to RTU vials.”
For more information, visit www.stevanatogroup.com or
www.gerresheimer.com.
About Stevanato Group
Founded in 1949, Stevanato Group is a leading global provider of
drug containment, drug delivery and diagnostic solutions to the
pharmaceutical, biotechnology and life sciences industries. The
Group delivers an integrated, end-to-end portfolio of products,
processes and services that address customer needs across the
entire drug life cycle at each of the development, clinical and
commercial stages. Stevanato Group’s core capabilities in
scientific research and development, its commitment to technical
innovation and its engineering excellence are central to its
ability to offer value added solutions to clients. To learn more,
visit: www.stevanatogroup.com.
About Gerresheimer AG
Gerresheimer AG is the global partner for pharmaceutics,
biotech, healthcare, and cosmetics with a very broad product range
for pharmaceutical and cosmetic packaging solutions and drug
delivery systems. The company is an innovative solution provider
from concept to delivery of the commercial product. Gerresheimer
achieves its ambitious goals through a high level of innovative
strength, industrial competence and concentration on quality and
customer focus. In developing innovative and sustainable solutions,
Gerresheimer relies on a comprehensive international network with
numerous innovation and production centers in Europe, America and
Asia. Gerresheimer produces close to its customers worldwide with
around 11,000 employees and generated annual revenues in 2021 of
around EUR 1.5b. With its products and solutions, Gerresheimer
plays an essential role in people's health and well-being.
www.gerresheimer.com
Forward-looking statements
This press release may include forward-looking statements. The
words "projected ", "expect", “aims”, and similar expressions (or
their negative) identify certain of these forward-looking
statements. These forward-looking statements are statements
regarding the Companies’ intentions, beliefs or current
expectations concerning the collaboration. The forward-looking
statements in this press release are based on numerous assumptions
regarding the Companies’ present and future business strategies and
the environment in which each Company will operate in the future.
Forward-looking statements involve inherent known and unknown
risks, uncertainties and contingencies because they relate to
events and depend on circumstances that may or may not occur in the
future and may cause the actual results, performance or
achievements of the Companies to be materially different from those
expressed or implied by such forward-looking statements. Many of
these risks and uncertainties relate to factors that are beyond the
Companies' ability to control or estimate precisely, such as future
market conditions, currency fluctuations, the behavior of other
market participants, the actions of regulators and other factors
such as the Companies' ability to continue to obtain financing to
meet its liquidity needs, changes in the political, social and
regulatory framework in which the Company operates or in economic
or technological trends or conditions. Readers should therefore not
place undue reliance on these statements, particularly not in
connection with any contract or investment decision. Except as
required by law, none of the companies assumes no obligation to
update any such forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220907005488/en/
Contact Media Stevanato Group: media@stevanatogroup.com
Cassie Gonzalez: stevanatoUS@teamlewis.com
Investor Relations Stevanato Group: Lisa Miles:
lisa.miles@stevanatogroup.com
Contact Press Gerresheimer AG: Ueli Utzinger Group Senior
Director Marketing & Communication T +49 211 6181-250
ueli.utzinger@gerresheimer.com
Contact Investor Relations Gerresheimer AG: Carolin
Nadilo Corporate Senior Director Investor Relations T +49 211
6181-220 carolin.nadilo@gerresheimer.com
Stevanato (NYSE:STVN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Stevanato (NYSE:STVN)
Historical Stock Chart
From Apr 2023 to Apr 2024